2seventy bio (NASDAQ:TSVT) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 2seventy bio (NASDAQ:TSVT) in a research report sent to investors on Saturday,Weiss Ratings reports.

2seventy bio Price Performance

NASDAQ:TSVT traded up $0.17 during trading hours on Friday, reaching $2.61. 380,020 shares of the company were exchanged, compared to its average volume of 398,038. 2seventy bio has a 52-week low of $2.35 and a 52-week high of $6.40. The stock has a 50 day simple moving average of $3.28 and a 200 day simple moving average of $4.15. The firm has a market cap of $134.65 million, a price-to-earnings ratio of -1.40 and a beta of 1.76.

Hedge Funds Weigh In On 2seventy bio

Several hedge funds and other institutional investors have recently modified their holdings of TSVT. BBR Partners LLC increased its position in 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock worth $850,000 after purchasing an additional 155,000 shares in the last quarter. Geode Capital Management LLC grew its stake in 2seventy bio by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock worth $5,553,000 after buying an additional 13,144 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of 2seventy bio in the third quarter worth $64,000. FMR LLC raised its stake in shares of 2seventy bio by 22.0% in the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after acquiring an additional 26,738 shares during the period. Finally, XTX Topco Ltd lifted its holdings in shares of 2seventy bio by 61.1% during the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after acquiring an additional 9,257 shares in the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.